{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:36:25Z","timestamp":1776868585696,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01532-4","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:11:33Z","timestamp":1773123093000},"page":"571-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib"],"prefix":"10.1007","volume":"46","author":[{"given":"Xuefei","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjie","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"4","key":"1532_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hon.2202","volume":"34","author":"XM Wang","year":"2016","unstructured":"Wang XM, Bassig BA, Wen JJ, Li GD, Liu ZB, Yao WX, et al. Clinical analysis of 1629 newly diagnosed malignant lymphomas in current residents of Sichuan province, China. Hematol Oncol. 2016;34(4):193\u20139.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1532_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","volume":"22","author":"QP Yang","year":"2011","unstructured":"Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;22(6):77.","journal-title":"Diagn Pathol"},{"issue":"3","key":"1532_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3324\/haematol.2022.281421","volume":"108","author":"P Ghione","year":"2023","unstructured":"Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, et al. Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108(3):822\u201332.","journal-title":"Haematologica"},{"issue":"7","key":"1532_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000745","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, et al. A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL). Hemasphere. 2022;6(7):e745.","journal-title":"Hemasphere"},{"issue":"7","key":"1532_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74.","journal-title":"Blood Cancer J"},{"key":"1532_CR6","volume-title":"Guidelines of the Chinese Society of Clinical Oncology (CSCO) for Lymphoma 2024","author":"Oncology CSoC","year":"2024","unstructured":"Oncology CSoC. Guidelines of the Chinese Society of Clinical Oncology (CSCO) for Lymphoma 2024. Beijing: People\u2019s Medical Publishing House; 2024."},{"issue":"22","key":"1532_CR7","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/092986709788803222","volume":"16","author":"D Kong","year":"2009","unstructured":"Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 2009;16(22):2839\u201354.","journal-title":"Curr Med Chem"},{"key":"1532_CR8","volume-title":"Guidelines of the Chinese Society of Clinical Oncology (CSCO) for Lymphoma 2023","author":"Oncology CSoC","year":"2023","unstructured":"Oncology CSoC. Guidelines of the Chinese Society of Clinical Oncology (CSCO) for Lymphoma 2023. Beijing: People\u2019s Medical Publishing House; 2023."},{"issue":"8","key":"1532_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","volume":"29","author":"T Wang","year":"2023","unstructured":"Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, et al. The Oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial. Clin Cancer Res. 2023;29(8):1440\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1532_CR10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40273-019-00812-6","volume":"37","author":"TE Delea","year":"2019","unstructured":"Delea TE, Zhang X, Amdahl J, Boyko D, Dirnberger F, Campioni M, et al. Cost effectiveness of Blinatumomab versus Inotuzumab Ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics. 2019;37(9):1177\u201393.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1532_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"1","key":"1532_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97\u2013108.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1532_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1532_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.jval.2024.04.003","volume":"27","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Ray MD, Rosettie KL, Ball G, Jacob J, Bilir SP, et al. Cost-Effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States. Value Health. 2024;27(8):1030\u20138.","journal-title":"Value Health"},{"issue":"10","key":"1532_CR15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1080\/13696998.2018.1489254","volume":"21","author":"GF Guzauskas","year":"2018","unstructured":"Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. J Med Econ. 2018;21(10):960\u20137.","journal-title":"J Med Econ"},{"issue":"11","key":"1532_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1532_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jval.2022.07.002","volume":"26","author":"S Smith","year":"2023","unstructured":"Smith S, de Albuquerque Almeida F, In\u00eas M, Iadeluca L, Cooper M. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Value Health. 2023;26(1):64\u201370.","journal-title":"Value Health"},{"issue":"12","key":"1532_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;1(12):9.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1532_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1080\/13696998.2023.2254162","volume":"26","author":"T Mizuoka","year":"2023","unstructured":"Mizuoka T, Sakamaki H, Fuji S, Saito S, Murata T, Ohno S, et al. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan. J Med Econ. 2023;26(1):1122\u201333.","journal-title":"J Med Econ"},{"key":"1532_CR20","unstructured":"National Institute for Health and Care Excellence. Lenalidomide with rituximab for previously treated follicular lymphoma. London: NICE; 2020. Report No.: TA423."},{"key":"1532_CR21","unstructured":"National Institute for Health and Care Excellence. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. London: NICE; 2016. Report No.: TA423."},{"key":"1532_CR22","volume-title":"China guidelines for pharmacoeconomic evaluations 2020","author":"L Guoen","year":"2020","unstructured":"Guoen L. China guidelines for pharmacoeconomic evaluations 2020. Beijing: China Market Press; 2020."},{"issue":"5","key":"1532_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","volume":"7","author":"C Kunal","year":"2023","unstructured":"Kunal C, Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801\u201310.","journal-title":"Blood Adv"},{"issue":"1","key":"1532_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/13696998.2024.2352820","volume":"27","author":"M Matasar","year":"2024","unstructured":"Matasar M, Sanchez Alvarez J, Paris\u00e9 H, Zuk E, Di Maio D, Shapouri S, et al. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2024;27(1):766\u201376.","journal-title":"J Med Econ"},{"key":"1532_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393939","volume":"15","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Ray MD, Zur RM, Ferrufino CP, Doble B, Patel AR, et al. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States. Front Immunol. 2024;15:1393939.","journal-title":"Front Immunol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01532-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:39:47Z","timestamp":1776865187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01532-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no other conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The model developed during the current study is not publicly available due to confidentiality. The input data supporting the model are from previously reported publications and reports, which have been cited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"XB and RS contributed equally to this work. XB, RS and XH contributed to conception and study design. XB and RS took responsibility for the collection, integrity, and accuracy of the data. All authors drafted the manuscript, participated in data analyses and interpretation, and revisions of the manuscript and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}